Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.
Sandra P. D'Angelo, MD
Advertisement
Articles by Sandra P. D'Angelo, MD
Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.
Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.
Advertisement
Latest Updated Articles
Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in SarcomasSeptember 3rd 2019
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5